10-K Filing

ENVERIC BIOSCIENCES, INC. CIK: 890821 FY 2021

Filing Information

Form Type	10-K
Accession Number	`0001493152-22-008510`
Period End Date	20211231
Filing Date	20220331
Fiscal Year	2021
Fiscal Period	FY
XBRL Instance	form10-k_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 63 Income Statement 34 Cash Flow Statement 88 Stockholders Equity 35

Balance Sheet 63 line items

Line Item	Tag	Value	Unit	Period
Cash	`Cash`	$17.36M	USD	Point-in-time
Cash	`Cash`	$1.58M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$380.84K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$700.71K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$2.28M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$17.74M	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	-	USD	Point-in-time
Preferred Stock, Shares Authorized	`PreferredStockSharesAuthorized`	20.00M	shares	Point-in-time
Preferred Stock, Shares Authorized	`PreferredStockSharesAuthorized`	20.00M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$294.43K	USD	Point-in-time
Right of use operating lease asset	`OperatingLeaseRightOfUseAsset`	-	USD	Point-in-time
Right of use operating lease asset	`OperatingLeaseRightOfUseAsset`	$176.30K	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$6.92M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$1.82M	USD	Point-in-time
Goodwill	`Goodwill`	-	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Goodwill	`Goodwill`	$1.59M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common Stock, Shares Authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Total other assets	`AssetsNoncurrent`	$1.82M	USD	Point-in-time
Total other assets	`AssetsNoncurrent`	$8.98M	USD	Point-in-time
Total assets	`Assets`	$4.10M	USD	Point-in-time
Total assets	`Assets`	$26.72M	USD	Point-in-time
Common Stock, Shares, Issued	`CommonStockSharesIssued`	32.58M	shares	Point-in-time
Common Stock, Shares, Issued	`CommonStockSharesIssued`	10.10M	shares	Point-in-time
Common Stock, Shares, Outstanding	`CommonStockSharesOutstanding`	10.10M	shares	Point-in-time
Common Stock, Shares, Outstanding	`CommonStockSharesOutstanding`	32.58M	shares	Point-in-time
Accounts payable	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$683.39K	USD	Point-in-time
Accounts payable	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$681.25K	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	-	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$1.29M	USD	Point-in-time
Current portion of right-of-use operating lease obligation	`OperatingLeaseLiabilityCurrent`	$107.44K	USD	Point-in-time
Current portion of right-of-use operating lease obligation	`OperatingLeaseLiabilityCurrent`	-	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$681.25K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.08M	USD	Point-in-time
Non-current portion of right-of-use operating lease obligation	`OperatingLeaseLiabilityNoncurrent`	-	USD	Point-in-time
Non-current portion of right-of-use operating lease obligation	`OperatingLeaseLiabilityNoncurrent`	$68.86K	USD	Point-in-time
Deferred tax liability	`DeferredIncomeTaxLiabilities`	$1.61M	USD	Point-in-time
Deferred tax liability	`DeferredIncomeTaxLiabilities`	-	USD	Point-in-time
Warrant liability	`WarrantLiabilitiesNoncurrent`	$653.67K	USD	Point-in-time
Warrant liability	`WarrantLiabilitiesNoncurrent`	-	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	-	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$2.33M	USD	Point-in-time
Total liabilities	`Liabilities`	$681.25K	USD	Point-in-time
Total liabilities	`Liabilities`	$4.41M	USD	Point-in-time
Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, and 3,275,407 shares issued and outstanding as of December 31, 2021 and 2020, respectively	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, and 3,275,407 shares issued and outstanding as of December 31, 2021 and 2020, respectively	`PreferredStockValue`	$32.75K	USD	Point-in-time
Common stock, $0.01 par value, 100,000,000 shares authorized, 32,578,475 and 10,095,109 shares issued and outstanding as of December 31, 2021 and 2020, respectively	`CommonStockValue`	$325.79K	USD	Point-in-time
Common stock, $0.01 par value, 100,000,000 shares authorized, 32,578,475 and 10,095,109 shares issued and outstanding as of December 31, 2021 and 2020, respectively	`CommonStockValue`	$100.95K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$15.22M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$82.75M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-11.76M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-60.74M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-30.80K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-181.28K	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$22.31M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$-1.81M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$3.42M	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$4.10M	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$26.72M	USD	Point-in-time

Income Statement 34 line items

Line Item	Tag	Value	Unit	Period
Research and development costs	`ResearchAndDevelopmentExpense`	$4.79M	USD	Annual
Research and development costs	`ResearchAndDevelopmentExpense`	$174.08K	USD	Annual
General and administrative expenses	`SellingGeneralAndAdministrativeExpense`	$20.50M	USD	Annual
General and administrative expenses	`SellingGeneralAndAdministrativeExpense`	$5.32M	USD	Annual
Impairment of intangible assets and goodwill	`GoodwillAndIntangibleAssetImpairment`	-	USD	Annual
Impairment of intangible assets and goodwill	`GoodwillAndIntangibleAssetImpairment`	$38.68M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$120.87K	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$656.64K	USD	Annual
Total operating expenses	`OperatingCostsAndExpenses`	$64.62M	USD	Annual
Total operating expenses	`OperatingCostsAndExpenses`	$5.62M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-5.62M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-64.62M	USD	Annual
Interest expense	`InterestExpense`	$445.25K	USD	Annual
Interest expense	`InterestExpense`	$10.32K	USD	Annual
Change in fair value of warrant liabilities	`FairValueAdjustmentOfWarrants`	$-9.33M	USD	Annual
Change in fair value of warrant liabilities	`FairValueAdjustmentOfWarrants`	-	USD	Annual
Inducement expense	`InducementExpense`	$1.13M	USD	Annual
Inducement expense	`InducementExpense`	$802.11K	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$-1.25M	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$8.19M	USD	Annual
Net loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-6.86M	USD	Annual
Net loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-56.43M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	$-7.45M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	Annual
Net loss after income tax benefit	`NetIncomeLoss`	$-6.86M	USD	Annual
Net loss after income tax benefit	`NetIncomeLoss`	$-48.98M	USD	Annual
Foreign currency translation gain (loss)	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$150.47K	USD	Annual
Foreign currency translation gain (loss)	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-169.66K	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-48.83M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-7.03M	USD	Annual
Net loss per share basic and diluted	`EarningsPerShareBasicAndDiluted`	$-2.07	USD	Annual
Net loss per share basic and diluted	`EarningsPerShareBasicAndDiluted`	$-1.19	USD	Annual
Weighted average shares outstanding, basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.75M	shares	Annual
Weighted average shares outstanding, basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	23.62M	shares	Annual

Cash Flow Statement 88 line items

Line Item	Tag	Value	Unit	Period
Net Loss	`NetIncomeLoss`	$-6.86M	USD	Annual
Net Loss	`NetIncomeLoss`	$-48.98M	USD	Annual
Change in fair value of warrant liability	`FairValueAdjustmentOfWarrants`	$-9.33M	USD	Annual
Change in fair value of warrant liability	`FairValueAdjustmentOfWarrants`	-	USD	Annual
Stock issued in lieu of cash for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$33.47K	USD	Annual
Stock issued in lieu of cash for services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	-	USD	Annual
Stock-based compensation	`StockAndOptionsBasedCompensation`	$1.98M	USD	Annual
Stock-based compensation	`StockAndOptionsBasedCompensation`	$12.60M	USD	Annual
Accrued interest	`AccruedInterest`	$156.62K	USD	Annual
Accrued interest	`AccruedInterest`	-	USD	Annual
Amortization of debt discount	`AmortizationOfDebtDiscountPremium`	$288.63K	USD	Annual
Amortization of debt discount	`AmortizationOfDebtDiscountPremium`	-	USD	Annual
Inducement expense	`InducementExpense`	$1.13M	USD	Annual
Inducement expense	`InducementExpense`	$802.11K	USD	Annual
Amortization of right-of-use operating lease asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	-	USD	Annual
Amortization of right-of-use operating lease asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$24.97K	USD	Annual
Depreciation expense	`Depreciation`	-	USD	Annual
Depreciation expense	`Depreciation`	$13.31K	USD	Annual
Impairment of intangible assets and goodwill	`ImpairmentOfIntangibleAssetsAndGoodwill`	$38.68M	USD	Annual
Impairment of intangible assets and goodwill	`ImpairmentOfIntangibleAssetsAndGoodwill`	-	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$643.33K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$120.87K	USD	Annual
Non-cash income tax benefit	`NoncashIncomeTaxExpense`	$-7.45M	USD	Annual
Non-cash income tax benefit	`NoncashIncomeTaxExpense`	-	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-826.84K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$636.50K	USD	Annual
Accounts payable, and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$267.00K	USD	Annual
Accounts payable, and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$383.20K	USD	Annual
Right-of-use operating lease liability	`IncreaseDecreaseInRightOfUseLeaseLiability`	$24.97K	USD	Annual
Right-of-use operating lease liability	`IncreaseDecreaseInRightOfUseLeaseLiability`	-	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-11.46M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.89M	USD	Annual
Purchase of license agreements	`PaymentsToAcquireIntangibleAssets`	$44.14K	USD	Annual
Purchase of license agreements	`PaymentsToAcquireIntangibleAssets`	$675.00K	USD	Annual
Cash accretive acquisition of MagicMed	`ProceedsFromAmalgamationAgreement`	$3.06M	USD	Annual
Cash accretive acquisition of MagicMed	`ProceedsFromAmalgamationAgreement`	-	USD	Annual
Equipment purchases	`PaymentsToAcquireMachineryAndEquipment`	-	USD	Annual
Equipment purchases	`PaymentsToAcquireMachineryAndEquipment`	$189.72K	USD	Annual
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$2.19M	USD	Annual
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-44.14K	USD	Annual
Proceeds from convertible notes payable	`ProceedsFromConvertibleDebt`	$50.00K	USD	Annual
Proceeds from convertible notes payable	`ProceedsFromConvertibleDebt`	-	USD	Annual
Proceeds from note payable, net of offering costs	`ProceedsFromNotesPayable`	$1.81M	USD	Annual
Proceeds from note payable, net of offering costs	`ProceedsFromNotesPayable`	-	USD	Annual
Offering and reverse merger proceeds	`ProceedsFromOfferingAndReverseMergerProceeds`	$3.37M	USD	Annual
Offering and reverse merger proceeds	`ProceedsFromOfferingAndReverseMergerProceeds`	-	USD	Annual
Proceeds from sales of common stock and warrants, net	`ProceedsFromIssuanceOfCommonStock`	$488.00K	USD	Annual
Proceeds from sales of common stock and warrants, net	`ProceedsFromIssuanceOfCommonStock`	$21.61M	USD	Annual
Proceeds from exercise of cash warrants	`ProceedsFromIssuanceOfWarrants`	$3.29M	USD	Annual
Proceeds from exercise of cash warrants	`ProceedsFromIssuanceOfWarrants`	-	USD	Annual
Repayment of note payable	`RepaymentsOfNotesPayable`	$191.64K	USD	Annual
Repayment of note payable	`RepaymentsOfNotesPayable`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$24.90M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.53M	USD	Annual
Effect of foreign exchange rate on cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$144.94K	USD	Annual
Effect of foreign exchange rate on cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-63.60K	USD	Annual
Net increase in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.53M	USD	Annual
Net increase in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$15.78M	USD	Annual
Cash beginning of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$17.36M	USD	Point-in-time
Cash beginning of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.58M	USD	Point-in-time
Cash beginning of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$43.71K	USD	Point-in-time
Cash end of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$17.36M	USD	Point-in-time
Cash end of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.58M	USD	Point-in-time
Cash end of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$43.71K	USD	Point-in-time
Right-of-use assets obtained in exchange for lease liabilities	`RightofuseAssetsObtainedInExchangeForLeaseLiabilities`	$201.65K	USD	Annual
Right-of-use assets obtained in exchange for lease liabilities	`RightofuseAssetsObtainedInExchangeForLeaseLiabilities`	-	USD	Annual
Issuance of Common Stock pursuant to MagicMed amalgamation	`IssuanceOfCommonStockPursuantToAmalgamation`	$39.04M	USD	Annual
Issuance of Common Stock pursuant to MagicMed amalgamation	`IssuanceOfCommonStockPursuantToAmalgamation`	-	USD	Annual
Deferred tax liability incurred due to MagicMed amalgamation	`DeferredTaxLiabilityIncurredDueToAmalgamation`	$9.06M	USD	Annual
Deferred tax liability incurred due to MagicMed amalgamation	`DeferredTaxLiabilityIncurredDueToAmalgamation`	-	USD	Annual
Conversion of preferred stock to common stock	`ConversionOfPreferredStockToCommonStock`	$32.75K	USD	Annual
Conversion of preferred stock to common stock	`ConversionOfPreferredStockToCommonStock`	-	USD	Annual
Fair value of warrants issued	`FairValueOfWarrantsIssued`	-	USD	Annual
Fair value of warrants issued	`FairValueOfWarrantsIssued`	$9.98M	USD	Annual
Beneficial conversion feature issued with note payable	`BeneficialConversionFeatureIssuedWithNotePayable`	-	USD	Annual
Beneficial conversion feature issued with note payable	`BeneficialConversionFeatureIssuedWithNotePayable`	$17.85K	USD	Annual
Warrants issued in conjunction with notes payable	`WarrantsIssuedInConjunctionWithNotesPayable`	$32.15K	USD	Annual
Warrants issued in conjunction with notes payable	`WarrantsIssuedInConjunctionWithNotesPayable`	-	USD	Annual
Common stock issued for accounts payable	`StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable`	-	USD	Annual
Common stock issued for accounts payable	`StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable`	$756.52K	USD	Annual
Common stock issued in conjunction with note payable modification	`StockIssuedDuringPeriodValueCommonStockIssuedInConjunctionWithNotPayableModification`	-	USD	Annual
Common stock issued in conjunction with note payable modification	`StockIssuedDuringPeriodValueCommonStockIssuedInConjunctionWithNotPayableModification`	$101.71K	USD	Annual
Conversion of related party advances and notes payable into common stock	`ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock`	-	USD	Annual
Conversion of related party advances and notes payable into common stock	`ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock`	$679.57K	USD	Annual
Common stock issued for skincare license	`CommonStockIssuedForSkincareLicense`	$1.90M	USD	Annual
Common stock issued for skincare license	`CommonStockIssuedForSkincareLicense`	-	USD	Annual
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Cash paid for interest	`InterestPaidNet`	$10.32K	USD	Annual

Stockholders Equity 35 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$22.31M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$-1.81M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$3.42M	USD	Point-in-time
September 2020 private placement	`StockIssuedDuringPeriodValueIssuedPrivatePlacement`	$227.50K	USD	Annual
December 2020 private placement	`StockIssuedDuringPeriodValueIssuedPrivatePlacementOne`	$260.50K	USD	Annual
Acquisition of Tikkun Pharma IP	`StockIssuedDuringPeriodValueAcquisitions`	$1.90M	USD	Annual
Conversion of Series B preferred shares	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	-	USD	Annual
Conversion of Series B preferred shares	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$4.82M	USD	Annual
Exchange of warrants for common shares	`StockIssuedDuringPeriodValueIssuedExchangeOfWarrantsForCommonShares`	$841.88K	USD	Annual
Conversion of related party advance and notes payable	`StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne`	$679.57K	USD	Annual
Common stock issued for accounts payable	`StockIssuedDuringPeriodValueNewIssues`	$756.52K	USD	Annual
Warrants issued in conjunction with notes payable	`AdjustmentsToAdditionalPaidInCapitalWarrantIssued`	$32.15K	USD	Annual
Beneficial conversion feature issued with note payable	`AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature`	$17.85K	USD	Annual
Common stock issued in conjunction with note payable modification	`StockIssuedDuringPeriodValueCommonStockIssuedInConjunctionWithNotPayableModification`	-	USD	Annual
Common stock issued in conjunction with note payable modification	`StockIssuedDuringPeriodValueCommonStockIssuedInConjunctionWithNotPayableModification`	$101.71K	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$1.98M	USD	Annual
Conversion of Series B preferred stock to common stock	`StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesTwo`	-	USD	Annual
Merger with Ameri Holdings, Inc	`StockIssuedDuringPeriodValueAcquisitionsOne`	$650.00K	USD	Annual
Foreign currency translation gain	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$150.47K	USD	Annual
Foreign currency translation gain	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-169.66K	USD	Annual
Net Loss	`NetIncomeLoss`	$-6.86M	USD	Annual
Net Loss	`NetIncomeLoss`	$-48.98M	USD	Annual
January 2021 registered direct offering	`StockIssuedDuringPeriodValueIssuedDirectOfferingNet`	$4.62M	USD	Annual
February 2021 registered direct offering	`StockIssuedDuringPeriodValueIssuedDirectOfferingNetOne`	$7.02M	USD	Annual
Consideration paid pursuant to amalgamation agreement	`ConsiderationPaidPursuantToAmalgamationAgreement`	$39.04M	USD	Annual
Warrant exercise	`ExerciseOfWarrants`	$3.29M	USD	Annual
Cashless options exercise	`StockIssuedDuringPeriodValueStockOptionsExercised`	-	USD	Annual
Cashless options exercise, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	143,796.00	shares	Annual
Induced conversion of warrants and options to Common Stock	`StockIssuedDuringPeriodValueIssuedConverionOfWarrants`	$1.13M	USD	Annual
Stock-based compensation	`AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet`	$12.60M	USD	Annual
Common stock issued in lieu of cash for services	`StockIssuedDuringPeriodValueIssuedForServices`	$33.47K	USD	Annual
Common stock issued pursuant to exercise of warrant put rights	`StockIssuedDuringPeriodValueIssuedPursuantExerciseOfWarrant`	-	USD	Annual
Ending balance, value	`StockholdersEquity`	$22.31M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$-1.81M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$3.42M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.